Study wrapper · #1253
Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.
Editor's note
The direction of effect is consistent across outcomes and time points, which is notable, but this pooled estimate leans heavily on observational cohorts with moderate-to-serious confounding risk and substantial heterogeneity on several endpoints. Weight loss alone lowers intracranial pressure, so disentangling a drug-specific effect from the metabolic one is the central unresolved question. The abstract also pools the GLP-1 class without naming agents — earlier IIH work centered on exenatide, so readers should not assume semaglutide-specific data. Hypothesis-generating, as the authors say; the randomized trials it calls for are the real test.
Plain-language abstract
Idiopathic intracranial hypertension is a condition, most common in young women with obesity, where pressure builds inside the skull and can threaten vision. Pooling eight studies covering 13,243 patients, this meta-analysis found that people on GLP-1 receptor agonist drugs had roughly half the risk of optic-nerve swelling and meaningfully fewer headaches and visual disturbances over up to two years. The authors themselves rate the evidence as low-certainty because most of the underlying studies were observational.